Table 4.
Results of multivariate logistic regression analyses for response rate and grade III-IV adverse events in 104 patients determined for ERCC1 C118T polymorphism
| Factors | ORR† | III-IV Grade AE† | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | P | HR | 95% CI | P | |
| Neoadjuvant chemotherapy (yes vs. no) | 18.1 | 2.944–111.284 | 0.002 | |||
| Concurrent chemotherapy (yes vs. no) | 26.529 | 2.312-304.389 | 0.008 | |||
| ERCC1 C118T (C/T vs. C/C+T/T) | 6.035 | 2.114–17.226 | 0.001 | |||
†
Age and the number of chemotherapy cycles were included in all regression analyses as continuous variables. AE, adverse events; CI, confidence interval; ERCC1, excision repair cross-complementing group 1; OR, odds ratio; ORR, objective response rate.